A Deep Dive into the The SGN-70 Drug Vorsetuzumab represents a exciting approach in oncology, specifically targeting CD22 expressed on blood cancers. Developed by Seattle Genetics, the agent functions as an antibody-dependent cellular cytotoxicity (ADCC) inducer, stimulating the body's killing of cancer cells. Investigation have indicated encourag